The Scale of Africa’s Biosafety Double-Standard
This is a guest post from the BiotechBlog Intern, Fintan Burke. Fintan is a student at the School of Biotechnology […]
General Biotechnology
regulation
General Biotechnology
Speeding Time to Market Cost-Effectively
With the recent news of pharma’s frustration with more price controls around the world, John Avellanet, frequent Biotech Blog poster
General Biotechnology
Jim Greenwood on Data Exclusivity and Healthcare Innovation
Biotechnology Industry Organization CEO Jim Greenwood appeared on CNBC’s SquawkBox defending the case for data exclusivity protection for novel biologic
Jim Greenwood on Data Exclusivity and Healthcare Innovation Read Post »
General Biotechnology
An Overview of the Biopharmaceutical Landscape Ahead
John Avellanet, a frequent contributor to this blog, is giving a talk for my biotechnology management class at the NIH
An Overview of the Biopharmaceutical Landscape Ahead Read Post »
General Biotechnology, Guest content
Solving the FDA Crisis
Guest content from John Avellanet, managing director and principal of Cerulean Associates: Solving the FDA Crisis By John Avellanet, Managing
General Biotechnology
Introducing Biotech-U: Web-based courses on biotechnology
After months of effort, I’m pleased to announce the launch of Biotech U, a biotechnology education resource featuring web-based lessons
Introducing Biotech-U: Web-based courses on biotechnology Read Post »
General Biotechnology
When will the U.S. develop concise generic biologic rules?
A lot of people have been asking my opinion on when a concise generic biologic regulatory pathway will emerge in
When will the U.S. develop concise generic biologic rules? Read Post »
General Biotechnology
An appeal for generic biologic legislation
The following appeal for generic biologic legislation was sent in from Insmed via youtube. I’ve posted previously on the challenges
General Biotechnology
Drug approvals fall. Who's to blame?
The FDA approved 38 drugs through July this year, down 31 percent from 55 approvals for the same period last
General Biotechnology
Drug approvals fall. Who’s to blame?
The FDA approved 38 drugs through July this year, down 31 percent from 55 approvals for the same period last